Galligan A, Xu W, Fourlanos S, Nankervis A, Chiang C, Mant A M, Parente P, Rischin D, Krishnamurthy B, Sandhu S, Colman P G
Department of Diabetes and Endocrinology, Royal Melbourne Hospital.
Division of Cancer Medicine, Peter MacCallum Cancer Centre.
Diabet Med. 2018 Jun 16. doi: 10.1111/dme.13762.
In recent years, immune checkpoint blockade has become a standard therapy for a wide range of cancers. Adverse events including endocrinopathies result from the induction of autoimmunity.
We report a case series of nine individuals who presented with immunotherapy-induced type 1 diabetes between 2015-2017.
Onset of diabetes occurred within 12 weeks of commencing therapy. Anti- GAD antibodies were present in six people. Retrospective testing of islet antibodies in pre-treatment samples was possible in two people and this revealed anti-GAD seroconversion in the first and high anti-GAD titres pre and post-treatment in the second person. Six people had high risk HLA haplotypes. Clinical and genetic factors are described and compared with previously published cases. This article is protected by copyright. All rights reserved.
近年来，免疫检查点阻断已成为多种癌症的标准治疗方法。包括内分泌病在内的不良事件是由自身免疫的诱导引起的。
我们报告了一组9例病例，这些患者在2015年至2017年间出现了免疫治疗诱导的1型糖尿病。
糖尿病在开始治疗后的12周内发病。6人存在抗谷氨酸脱羧酶（GAD）抗体。对2人的治疗前样本进行胰岛抗体回顾性检测，发现第一人出现抗GAD血清转化，第二人治疗前后抗GAD滴度均很高。6人具有高风险的人类白细胞抗原（HLA）单倍型。描述了临床和遗传因素，并与先前发表的病例进行了比较。本文受版权保护。保留所有权利。
